

Bladder Cancer (Urothelial) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __ Neoadjuvant/Pre-Op __ Adjuvant/Post-Op
__ 1st Line __ 2nd Line __ 3rd Line __ 3rd Line+ __ Maint

ECOG Performance Status: _____ **ICD-10 Code:** _____

Goal of Treatment: __ Curative __ Non-Curative

Biomarkers/Characteristics: (select all that apply)

Platinum Resistant/Refractory? __ Yes __ No

Neoadjuvant Therapy | Clinical Stage II, III, or IV without evidence of metastases (cT2, cT3, cT4a, cT4b, M0)

___ **CMV:** cisplatin, methotrexate, and vinblastine 3 cycles

___ Gemcitabine (Gemzar) and cisplatin 4 cycles

Adjuvant Therapy | Stage I or II after TURBT* or following resection of recurrent or persistent disease

___ **BCG:** bacillus calmette-guerin, intravesical

Metastatic Disease | First line therapy (1st line)

___ Gemcitabine (Gemzar) and cisplatin†

Metastatic Disease | Second line therapy (2nd line)

___ Gemcitabine (Gemzar)

___ Paclitaxel

___ Pembrolizumab (Keytruda)

*TURBT: Transurethral resection of bladder tumor

†In the setting of recurrent/metastatic disease, a substitution of carboplatin for cisplatin will be considered a pathway option

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.